The Biosimilar Paradox
- 26 April 2023
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 130 (9) , 966-972
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Two-year outcomes of intravitreal ziv-afliberceptBritish Journal of Ophthalmology, 2018
- Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein OcclusionJAMA, 2017
- Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage PatientsOphthalmology, 2017
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Association of Compounded Bevacizumab With Postinjection EndophthalmitisJAMA Ophthalmology, 2015
- Evaluation of Compounded Bevacizumab Prepared for Intravitreal InjectionJAMA Ophthalmology, 2015
- A Brief History of Anti-VEGF for the Treatment of Ocular AngiogenesisThe American Journal of Pathology, 2012
- Safe Preparation and Administration of Intravitreal Bevacizumab InjectionsNew England Journal of Medicine, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006